Nathaly Segovia

ORCID: 0000-0001-8814-6095
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • RNA Interference and Gene Delivery
  • Advanced biosensing and bioanalysis techniques
  • Virus-based gene therapy research
  • DNA and Nucleic Acid Chemistry
  • Lipid Membrane Structure and Behavior
  • MicroRNA in disease regulation
  • Nanoparticle-Based Drug Delivery
  • Immunotherapy and Immune Responses

Institut de Ciència de Materials de Barcelona
2016-2021

Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine
2021

Centre for Research on Ecology and Forestry Applications
2016

Centro de Investigación Biomédica en Red
2016

Institut Químic de Sarrià
2014-2015

Universitat Ramon Llull
2014-2015

Of all the much hyped and pricy cancer drugs, benefits from promising siRNA small molecule drugs are limited. Lack of efficient delivery vehicles that would release drug locally, protect it degradation, ensure high transfection efficiency, precludes fulfilling its full potential. This work presents a novel platform for local sustained with efficiencies both in vitro vivo breast mice model. protection efficiency enabled by their encapsulation oligopeptide‐terminated poly(β‐aminoester) (pBAE)...

10.1002/adhm.201400235 article EN Advanced Healthcare Materials 2014-08-11

Abstract MicroRNAs (miRNAs) are small non‐coding endogenous RNAs, which attracting a growing interest as therapeutic molecules due to their central role in major diseases. However, the transformation of these biomolecules into drugs is limited unstability bloodstream, caused by nucleases abundantly present blood, and poor capacity enter cells. The conjugation miRNAs nanoparticles (NPs) could be an effective strategy for clinical delivery. Herein, engineering non‐liposomal lipid nanovesicles,...

10.1002/smll.202101959 article EN Small 2021-11-16

Event Abstract Back to Surface charge tunability as a powerful strategy control electrostatic interaction for highly efficient delivery of nucleic acids, using tailored oligopeptide-modified poly(beta-amino ester)s (PBAEs) Pere Dosta1, Nathaly Segovia1, Victor Ramos1 and Salvador Borros1 1 Institut Químic de Sarrià, Universitat Ramon Llull, Grup d’Enginyera Materials (GEMAT), Spain Introduction The clinical development synthetic vectors gene therapy is still far from optimal[1]. Since are...

10.3389/conf.fbioe.2016.01.00716 article EN cc-by Frontiers in Bioengineering and Biotechnology 2016-01-01
Coming Soon ...